A Phase III, Multicentre, Double Blinded Study In Patients With Chronic Hepatitis C Who Are Non-Responders To Prior Peginterferon Alpha + Ribavirin Therapy Comparing Treatment With Thymosin Alpha 1 + Peginterferon Alpha-2a Plus Ribavirin With Peginterferon Alpha-2a + Ribavirin + Placebo.

Trial Profile

A Phase III, Multicentre, Double Blinded Study In Patients With Chronic Hepatitis C Who Are Non-Responders To Prior Peginterferon Alpha + Ribavirin Therapy Comparing Treatment With Thymosin Alpha 1 + Peginterferon Alpha-2a Plus Ribavirin With Peginterferon Alpha-2a + Ribavirin + Placebo.

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Jan 2012

At a glance

  • Drugs Peginterferon alfa-2a; Ribavirin; Thymalfasin
  • Indications Hepatitis C
  • Focus Therapeutic Use
  • Sponsors sigma-tau SpA
  • Most Recent Events

    • 01 Jan 2012 Results published in the Journal of Viral Hepatitis.
    • 09 Aug 2010 Official title, actual end date (July 2009) added as reported by ClinicalTrials.gov.
    • 09 Aug 2010 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top